As a result of Sermorelin Growth Hormone (GHRH) Therapy, the increased volume of human growth hormone secreted by the stimulated pituitary gland is converted by the liver into IGF-1. The increased amount of IGF-1 in the blood stream results an increase in metabolism and growth of new cells within the body’s organs and bones. This treatment is prescribed for unlabeled use in adults to reverse the effects of aging, increase bone density, enhance the immune system, and strengthen the heart, as well as, other organs of the body. Since the increased volume of human growth hormone is produced by the body’s pituitary gland, the body’s endocrine system will not allow more growth hormone to be produced by the Sermorelin GH-RH stimulation of the pituitary than the body can safely process within the endocrine self-monitoring system.